Weight loss injections, particularly GLP-1 receptor agonists like semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro), have revolutionized obesity management, but questions about their cardiovascular safety remain a priority for patients and clinicians
Personalizing Tirzepatide Therapy With Genetic Insights Not everyone's appetite-control pathways respond identically to tirzepatide because genetic variations influence how strongly your GLP-1 and GIP receptors function
Research models explore faster recovery, connective tissue repair, and anti-inflammatory mechanisms, providing insights relevant to sports science
Either early signs are surfacing that GLP-1 trends are beginning to stall, or these products are simply going through the normal course of business with peak potential intact
The critical role of T cells in glucocorticoid-induced osteoporosis
This means Medicare beneficiaries prescribed Wegovy for weight loss cannot use Medicare coverage